TNFRSF18 is involved in immune activation, promoting T cell proliferation and enhancing anti-tumor immune responses, while HHLA2 plays a role in immune checkpoint regulation, suppressing T cell activation and contributing to immune evasion in the tumor microenvironment. The gene discussed is TNFRSF18; the disease is neoplasm.